Future human clinical trials are needed to validate the translational effects of these pathways in NAFLD treatment, particularly regarding the clinical safety and efficacy of TFEB activators or AMPK/mTOR modulators. Here, TFEB is linked to metabolic dysfunction-associated steatotic liver disease.